Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Postinduction molecular MRD in NPM1-mutated AML used to identify patients who benefit from allogeneic transplant in first complete remission. Level 2.

BloodPubMed 38364112